CCNL2

Cyclin-L2 · Q96S94 · CCNL2 on Sugi Atlas →

0 patent compounds predicted against CCNL2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CCNL2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients PHASE3UNKNOWN
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas PHASE2RECRUITING
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer PHASE2WITHDRAWN
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas PHASE1/PHASE2COMPLETED
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage PHASE2RECRUITING
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
A Study of Abemaciclib in Recurrent Glioblastoma PHASE2ACTIVE_NOT_RECRUITING
Abemaciclib + Pembrolizumab In Glioblastoma PHASE2WITHDRAWN
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. PHASE1/PHASE2COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer PHASE2COMPLETED
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer PHASE2COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
Study of AVZO-021 in Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
Abemaciclib With or Without Atezolizumab for mCRPC PHASE2COMPLETED
Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma PHASE1/PHASE2COMPLETED
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies PHASE1RECRUITING
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma PHASE1WITHDRAWN
Erlotinib in Treating Patients With Barrett Esophagus PHASE1UNKNOWN
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors PHASE1RECRUITING
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy nanUNKNOWN
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer nanCOMPLETED
The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CCNL2 binder may also engage these)

ProteinNameSimilarity
Q5I0H5 1.000 Q5I0H5 →
Q9JJA7 0.999 Q9JJA7 →
Q5ZJP9 0.999 Q5ZJP9 →
Q7ZVX0 0.995 Q7ZVX0 →
Q9UK58 0.995 Q9UK58 →
Q6GN15 0.995 Q6GN15 →
Q52KE7 0.993 Q52KE7 →
Q9R1Q2 0.992 Q9R1Q2 →
Q5BKF8 0.991 Q5BKF8 →
G5EBX3 0.988 G5EBX3 →
B3M301 0.986 B3M301 →
Q2RAC5 0.985 Q2RAC5 →
Q14AX6 0.985 Q14AX6 →
Q7TQK0 0.985 Q7TQK0 →
CCNT1 Cyclin-T1 0.984 landscape →
BRPF3 Bromodomain and PHD finger-containing protein 3 0.984 landscape →
Q3MJK5 0.984 Q3MJK5 →
Q8HXN7 0.984 Q8HXN7 →
CCNT2 Cyclin-T2 0.984 landscape →
Q5HZJ0 0.984 Q5HZJ0 →
Q9QWV9 0.984 Q9QWV9 →
B4NBP4 0.984 B4NBP4 →
Q80TZ9 0.984 Q80TZ9 →
Q9CSP9 0.984 Q9CSP9 →
Q9XT26 0.983 Q9XT26 →
Q5TKR9 0.983 Q5TKR9 →
KDM4B Lysine-specific demethylase 4B 0.983 landscape →
Q9NRR4 0.983 Q9NRR4 →
Q06846 0.983 Q06846 →
MAP4K4 Mitogen-activated protein kinase kinase kinase kinase 4 0.983 landscape →